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ORIGINAL ARTICLE

Role of chromodomain helicase DNA-binding protein 2 in DNA damage
response signaling and tumorigenesis
P Nagarajan1,4, TM Onami2, S Rajagopalan1, S Kania3, R Donnell3 and S Venkatachalam1
1
Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, USA; 2Department of
Microbiology, University of Tennessee, Knoxville, TN, USA and 3Department of Pathobiology, University of Tennessee, Knoxville,
TN, USA

The chromodomain helicase DNA-binding proteins
(CHDs) are known to affect transcription through their
ability to remodel chromatin and modulate histone
deacetylation. In an effort to understand the functional
role of the CHD2 in mammals, we have generated a Chd2
mutant mouse model. Remarkably, the Chd2 protein
appears to play a critical role in the development,
hematopoiesis and tumor suppression. The Chd2 heterozygous mutant mice exhibit increased extramedullary
hematopoiesis and susceptibility to lymphomas. At the
cellular level, Chd2 mutants are defective in hematopoietic
stem cell differentiation, accumulate higher levels of the
chromatin-associated DNA damage response mediator,
cH2AX, and exhibit an aberrant DNA damage response
after X-ray irradiation. Our data suggest a direct role for
the chromatin remodeling protein in DNA damage
signaling and genome stability maintenance.
Oncogene (2009) 28, 1053–1062; doi:10.1038/onc.2008.440;
published online 12 January 2009
Keywords: chromatin remodeling; lymphoma; hematopoiesis; mutant mice; tumor suppressor and DNA
damage

Introduction
Chromatin remodeling serves as an important regulator
of various DNA processes including replication, transcription, recombination and DNA repair (Wu, 1997;
Bernstein et al., 2002; Hasan and Hottiger, 2002; Qin
and Parthun, 2002; Osley et al., 2007). The remodeling
of chromatin has also been implicated in physiological
processes as diverse as embryonic development and
cancer (Muller and Leutz, 2001; Wang et al., 2007a, b).
The chromodomain helicase DNA-binding proteins
(CHDs) were characterized as a distinct family of
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proteins in the 1990s (Woodage, 1997). The CHD genes
are evolutionarily conserved, and at least nine genes
have been identiﬁed in vertebrates ((Delmas et al., 1993;
Schuster, 2002) and (NCBI, assembly: 36)). The various
protein domains in these proteins are the chromodomain (Chromatin organization modiﬁer), SNF2-related
ATP-dependent helicase domain, speciﬁc DNA-binding
domains, PHD Zn-ﬁnger domains and the C-terminal
helicase domain (Woodage, 1997). The chromodomain
was initially characterized in Drosophila HP1 and
Polycomb proteins (Paro and Hogness, 1991). Chromodomain-containing proteins can self-associate and also
interact with the heterochromatic regions at centromeres, telomeres and polytene chromosomes (Singh
et al., 1991; Cowell and Austin, 1997). The CHD1
protein was initially characterized as a protein that
bound to immunoglobulin promoter sequences and later
analyses showed that the protein bound to decondensed
chromosomes and A þ T-rich sequences by its unique
high mobility group (HMG)-1-binding domain (Delmas
et al., 1993; Stokes and Perry, 1995). In addition to its
DNA-binding properties, CHD1 was also shown to
function as a chromatin assembly factor that has the
ability to transfer histones to DNA in vitro and interact
with transcription elongation factors (Simic et al., 2003;
Lusser et al., 2005). Substantial data on the CHD family
of proteins have come from biochemical studies on
human CHD3 and CHD4, in which they were shown to
be components of nucleosome remodeling and histone
deacetylase complexes (Targoff and Reichlin, 1985;
Tong et al., 1998; Xue et al., 1998; Zhang et al., 1998;
Brehm et al., 2000). Patients with the autoimmune
condition dermatomyositis produce antibodies against
CHD3 and CHD4 and are prone to increased susceptibility to cancer (Targoff and Reichlin, 1985; Takeda
and Dynan, 2001). More recently, the CHD5 gene has
been identiﬁed as a tumor suppressor gene residing in 1q
locus of human chromosome (Bagchi et al., 2007).
Interestingly, mutations in another CHD family member, CHD7, have been shown to lead to CHARGE
syndrome, a complex multiorgan disorder that includes
Coloboma, Heart defects, choanal Atresia, mental
Retardation, Genital and Ear anomalies and scoliosis
(Vissers et al., 2004; Lalani et al., 2006; Gao et al., 2007).
Recent in vitro studies have shown that the chromodomains present in CHD1 bind to speciﬁc histone H3
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methylated sites associated with activated transcription
(Flanagan et al., 2005; Pray-Grant et al., 2005; Sims
et al., 2005). Unlike any other CHD family member, the
CHD1 and CHD2 proteins contain the A þ T-hook
motif (also known as HMG1 domain) that is also
present in the HMG proteins (Thomas, 2001). Furthermore at the protein level, the CHD2 protein shares a
high degree of homology with CHD1, which has been
implicated in transcription and chromatin assembly
(Woodage, 1997; Jones et al., 2000; Tran, 2000; Simic
et al., 2003; Lusser et al., 2005). However, the
physiological role of CHD2 and its in vivo effects on
transcription are yet to be discerned, and recent studies
suggest a role for Chd2 in mammalian development and
survival (Marfella et al., 2006). In this study, we show
that the Chd2 protein functions as a tumor suppressor
gene and plays a potential role in modulating DNA
damage responses at the chromatin level.
Results
Chd2 is an essential gene in mice
In an effort to understand the role of Chd2 in
mammalian development and physiology, we generated
a Chd2 mutant mouse model using the Baygenomics
gene trap embryonic stem (ES) cell resource (Supplementary information and Supplementary Figure 1)
(Stryke et al., 2003). Genotype analysis of the embryos
and offspring obtained from F1 heterozygous intercrosses indicated that the Chd2 mutation led to
embryonic and perinatal lethality (data not shown).
Interestingly, the proportion of heterozygotes obtained
from the intercrosses was also less than the expected 2:1
ratio of the total offspring and this was further
conﬁrmed in crosses between heterozygous males and
wild-type females (Supplementary Table 1). Morphological analysis of the heterozygous and homozygous
mutant embryos at E12.5 showed a drastic reduction in
the formation of vascular structures and regions of
localized hemorrhaging (Figure 1a). Further analysis of
the reduced vasculature of the Chd2 homozygous
mutant embryos showed a substantial decrease in
PECAM-1 staining in the peripheral vascular structures,
indicative of defective vascular wall integrity in a subset
set of mutants (data not shown). Interestingly, the
hemorrhages were also present in some of the heterozygous mutants and this could explain the partial
lethality of the heterozygous animals.
The developmental phenotypes of the heterozygous
and the homozygous mutant animals strongly suggested
that the Chd2 gene is essential for development.
However, studies by other groups that have used gene
trap-based knockdown of speciﬁc genes have shown that
the effectiveness of the gene trap is variable and may
lead to the generation of hypomorphic mutants (Voss
et al., 1998; Gonzalez-Billault et al., 2000; Fukasawa
et al., 2006). To ascertain the effectiveness of the gene
trap on knocking down the expression of wild-type Chd2
(by affecting the splicing between exons 27 and 28) and
rule out any leaky expression of the wild-type gene in the
Oncogene

homozygous mutants, we determined the expression of
wild-type Chd2 in homozygous mutant cells and
embryos in reverse transcription–PCR assays. Surprisingly, we found that the homozygous mutants did
express the wild-type mRNA albeit at lower levels
(Supplementary Figure 2). The ineffective downregulation of Chd2 may lead to the generation of a
hypomorphic allele or a dominant negative allele (by
the interaction of the Chd2-b-gal-neomycin fusion
peptide with the wild-type protein). To test this
possibility of dominant negative effects, we analysed
the inter-molecular interactions between recombinant
Chd2 peptides that contained 6x-His and HA epitope
tags. As shown in Supplementary Figure 3, reciprocal
immunoprecipitation analysis of recombinant Chd2
peptides showed that they were able to interact with
each other. These results suggest that the Chd2-b-galneomycin fusion protein may either sequester the
wild-type Chd2 protein to the cytoplasm or compete
with the native protein for its binding partners.
However, our results do not rule out the possibility
that the Chd2-bgeo fusion protein could also function as
a gain of function mutant.
Chd2 affects hematopoietic stem cell differentiation
Extensive histological examination of the neonates did
not reveal any gross anatomical differences between the
wild-type and mutant animals, except for the occasional
atrial enlargement in the mutants. Owing to the
extremely limited quantities of peripheral blood available in the neonates, we were unable to perform a
complete blood analysis of the newborn pups. However,
examination of the neonatal livers of the mutants
indicated that the hematopoietic cell distribution was
different in the mutants that showed an increase in the
number of megakaryocytes (Figure 1c). Furthermore,
the hematopoietic cell islands were less organized in the
mutants in comparison with the wild-type neonates that
showed well-organized clusters of hematopoietic cells
(Figures 1b and c). The localized hemorrhages and
increased megakaryocytes in the mutant animals suggested a role for the Chd2 protein in hematopoietic stem
cell differentiation. To test this possibility, we analysed
the lineage-speciﬁc differentiation potential of hematopoietic stem cells and found that the Chd2 mutant cells
were defective in their ability to differentiate into the
erythroid lineage (Figure 1d). The lowered capacity of
erythrocyte differentiation in Chd2 mutants were further
conﬁrmed in ﬂuorescence activated cell-sorting analyses
using ﬂow cytometry. The differentiation of erythroblasts to erythrocytes can be assessed by analysing and
quantitating the expression of cell surface markers
Ter119, CD71 and CD117 (Kina et al., 2000; Socolovsky et al., 2001; Zhang et al., 2003; Spike et al., 2004).
During erythroid maturation, the expression of CD71
decreases from proerythroblasts to early basophilic
erythroblasts, whereas the expression of the Ter119
remains high (Socolovsky et al., 2001). As shown in
Supplementary Figure 4, there was an increase in the
percentage of CD71 þ Ter119 cells in the mutants (27.9
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Figure 1 Analysis of the developmental phenotypes in Chd2 mutant mice. (a) Morphological phenotypes of Chd2 mutant embryos.
E12.5 embryos were harvested and photographed. (b) Hematopoietic cell distribution and organization defects in mutant neonates.
Representative images of hematoxylin and eosin (H&E)-stained sections of wild type (WT) and homozygous mutant neonatal liver
sections are shown. The megakaryocytes are circled. (c) Increased megakaryocytes in Chd2 mutant mice. A total of 10 different ﬁelds
were counted from H&E-stained sections of neonatal fetal livers from each group (n ¼ 7). The differences between the wild-type and the
mutants were statistically signiﬁcant as determined by single-tailed t-test (WT v. þ /m, Po0.002 and WT v. m/m, Po0.005). Error
bars represent s.e. (d) Hematopoietic stem cell differentiation defects in Chd2 mutants. Burst-forming unit-erythroid (BFU-E) and
colony-forming unit-granulocyte macrophage (CFU-GM) formation in wild-type (n ¼ 5), Chd2 þ /m (n ¼ 5) and Chd2m/m (n ¼ 8) were
assayed using E13.5 fetal liver progenitor cells as described. The differences between the wild-type and the homozygous mutants were
statistically signiﬁcant as determined by single-tailed t-test (WT v. m/m, Po0.00005). Error bars represent s.e.

and 25.0%) in comparison with the wild-type fetal livers
(9%). A concomitant reduction in the number of
double-positive CD71 þ Ter119 þ cells is also observed
in the mutants (87.6% in wild type versus 60.5 and
54.7% in mutants). Similar results were obtained from
the ﬂuorescence activated cell-sorting analysis proﬁles of
erythroid progenitors stained with Ter119 and CD117
(Supplementary Figure 4, bottom panel).
Chd2 deﬁciency leads to lymphomas
The heterozygous offspring that survived beyond the
perinatal stage did not show any overt developmental
abnormalities except for an apparent reduction in size at
birth that was less pronounced in mice that were 3–4
months old. However, after 8–10 months of age the

heterozygous mice began to exhibit weight loss, lordokyphosis (hunch-back spine) and loss of vitality.
Interestingly, the lordokyphosis phenotype of the
Chd2 mutant mice resembles the vertebral abnormalities
found in human patients with mutations in CHD7 and
CHD2 (Gao et al., 2007; Kulkarni et al., 2008). Survival
analysis showed drastic reduction in the lifespan of the
Chd2 heterozygous mutant mice (median lifespan of
52.3 weeks (Figure 2a)). Histological examination of
organs harvested from morbid mice showed that a
majority of the mice were succumbing to splenic,
lymphnode and thymic lymphomas as well as lymphoid
hyperplasias (Figures 2b–e, and Table 1). The earliest
incidence of lymphomas in the mutant mice was at 26
weeks of age and a majority of the mice (14/21) had
succumbed to lymphomas within 58 weeks. In comparison,
Oncogene
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Figure 2 Lymphoid tumor susceptibility and hematopoietic defects in Chd2 mutant mice. (a) Kaplan–Meier survival curves of Chd2
mutant and wild-type littermates (n ¼ 50). The percentages of survival are plotted as a function of age in weeks. Animals were
monitored for tumors, morbidity or spontaneous death over a period of 105 weeks. Of the 74 animals analysed for each group, 50 of
the heterozygous mutants died in comparison with 6 for the wild-type controls during a period of 2 years. All mice were of mixed
inbred C57BL/6X129/Sv background. (b–f) Representative images of hematoxylin and eosin-stained sections of a normal spleen from
an age-matched wild-type mouse (b), lymphoid hyperplasia (c), lymphoma (d and e) and extramedullary hematopoiesis from
heterozygous mice (f) are shown.

Table

1 Distribution

of pathological
heterozygous mice

Lymphoma
Lymphoid hyperplasia
Extramedullary hematopoiesisa (EMH)
Glomerulo-nephropathyb
Inﬂammation of heart/arteryc
Other cancersd

conditions
43.7%
31.2%
39.6%
46.8%
43.2%
4.1%

in

Chd2

(21 of 48)
(15 of 48)
(19 of 48)
(15 of 32)
(16 of 37)
(2 of 48)

Tissues from a total of 48 mice were analysed to determine the reasons
for morbidity. Hearts were examined for 37 mice. To avoid overestimation of lymphoid hyperplasias, animals showing lymphomas as
well as lymphoid hyperplasias (in other organs) were categorized under
lymphomas.
a
13 out of 19 animals diagnosed with EMH showed either lymphoid
hyperplasia or lymphoma.
b
12 out of 15 animals showing nephropathy were diagnosed with either
lymphoid hyperplasia or lymphoma.
c
13 out of 16 animals diagnosed with arterial and heart inﬂammation
showed either lymphoid hyperplasia or lymphoma phenotypes.
d
Two animals were diagnosed with hemangiosarcoma and bronchoalveolar carcinoma.

only one out of the six wild-type mice was
diagnosed with lymphoma during the analysis period.
Wild-type mice also develop lymphomas as a function
of age, and such tumors account for about 5–20%
incidence as reported for mice of various genetic
backgrounds by others (Bronson and Lipman, 1991;
Venkatachalam et al., 1998; Jeganathan et al., 2007). In
addition to the lymphoid tumor phenotypes, a signiﬁcant proportion of the mice exhibited extramedullary
hematopoiesis and lymphoma-related pathologies
that included nephropathy and inﬂammation of the
Oncogene

heart/artery, as a majority of these animals exhibited a
concomitant lymphoid phenotype (Figure 2f and
Table 1). To determine whether the hyperplasias or
lymphomas were due to increased T or B cells, we
isolated lymphocytes from spleen and lymph nodes and
stained with antibodies speciﬁc for T and B cells. In
addition, we also used antibodies against the T-cell
activation marker CD44 and analysed the cells by
ﬂuorescence activated cell-sorting analysis. Although
the total lymphocyte numbers were increased in the
Chd2 heterozygous mice in spleen and lymph nodes,
there were no differences in the total number of B cells,
indicating that the observed hyperplasias and lymphomas were most likely unrelated to dysregulation of the
B-cell compartment (Figure 3b). However, analysis of T
cells in the Chd2 heterozygous mice showed signiﬁcantly
increased numbers of activated CD44 high CD4 T cells
in mice independently conﬁrmed with hyperplasia or
lymphomas by histopathology (Figures 3a and c). In
disease-free younger mutants, no differences were
observed in the proportion or number of activated
CD4 T cells (Supplementary Figure 5 and data not
shown). These data suggest that the hyperplasias and
lymphomas observed in Chd2 mice are due to dysregulation of activated T cells. Furthermore, expression
analysis of Chd2 transcripts in organs harvested from
wild-type adult mice showed a diverse expression
pattern with the highest expression in thymus followed
by lungs, kidneys, spleen, heart, testis and liver
(Supplementary Figure 6). The highest expression of
Chd2 in the thymus provides additional evidence for the
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Figure 3 Characterization of lymphoid hyperplasias and lymphomas in Chd2 mutant mice. (a) Total number of activated T cells from
the spleens of age-matched wild type, Chd2 mutants with hyperplasia, and Chd2 mutants with lymphoma. (b) Total number of B cells
from spleens of indicated mice. (c) Representative ﬂuorescence activated cell-sorting proﬁle showing CD4 and CD44 expression of cells
from the lymph nodes of wild type, Chd2 heterozygous mutant with lymphoid hyperplasia and Chd2 heterozygous mutant with
lymphoma. In each group 3–4 mice were used; **indicates Po0.01 and ***indicates Po0.001.

tissue-speciﬁc induction of lymphomas in the Chd2
mutants. However, we cannot rule out the role of Chd2
on the induction of other phenotypes that occur in the
absence of the lymphoid phenotypes. Future studies that
utilize conditional inactivation of Chd2 in a tissuespeciﬁc manner would allow us to dissect the role of
Chd2 in speciﬁc organs.
The preponderance of lymphomas in the Chd2
mutant mice indicated that the loss of the CHD2 gene
might also be important in the development of human
cancers. We used the Mitelman database of Chromosomal aberrations in Cancer (Cancer Genome Anatomy
Project: http://cgap.nci.nih.gov/chromosome/Mitelman)
to determine if there are any chromosomal aberrations
in human cancers that colocalized with the CHD2
chromosomal locus (15q26). Systematic analysis and
categorization of 15q26 chromosomal abberations
showed that a substantial fraction (128/265, 48.3%) of
the reported human cancers with chromosomal aberrations in 15q26 were either lymphomas or leukemias
(Supplementary Table 2). Among the various chromosomal aberrations found in lymphomas and leukemias,
B15% of the aberrations were deletions.
Chd2 modulates DNA damage responses
On the basis of the observed susceptibility of the Chd2
mutant mice to lymphomas and the chromatin-binding
ability of Chd2, we hypothesized that the Chd2 protein
might affect genomic stability by regulating DNA
damage responses at the chromatin level. Phosphorylation of the histone variant, H2AX, at serine 139 (also

known as gH2AX) is one of the earliest events that
occurs at the chromatin level in response to DNA-strand
breaks and this modiﬁcation usually parallels the extent
of DNA damage (Rogakou et al., 1998; Banath and
Olive, 2003). Furthermore, studies have also shown the
recruitment of DNA repair proteins to ionizing radiation-induced gH2AX foci and mice deﬁcient for H2AX
show ionizing radiation sensitivity (Downs et al., 2000;
Paull et al., 2000; Kang et al., 2005). To examine the
possibility that the Chd2 mutant cells may have an
aberrant DNA damage response with respect to
gH2AX, we compared the levels of gH2AX in Chd2
mutant and wild-type mouse embryonic ﬁbroblasts
(MEFs) treated with low levels of X-ray irradiation.
We found several differences in the gH2AX patterns
between the wild-type and mutant cells. First, there was
a consistent sub-population of mutant controls (B25%)
that exhibited the presence of several gH2AX foci within
their nuclei that was signiﬁcantly higher in comparison
with the wild-type controls suggesting the presence of
DNA-strand breaks even without any external DNA
damage induction (Table 2). Second, as shown in
Figure 4, X-ray-induced DNA damage led to a higher
increase in gH2AX foci in Chd2 homozygous mutant
cells within 30 min in comparison with wild-type
littermate control cells. Furthermore, the gH2AX foci
were much more intense in the Chd2 mutant cells in
comparison with the wild-type cells treated similarly
indicative of higher levels of DNA damage (compare the
middle panels in Figure 4, Table 2). The initial induction
of gH2AX foci declines within a few hours of DNA
damage induction and this reduction is thought to occur
Oncogene
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Table 2
Treatment/genotype
Untreated control
4 Gy, 0.5 h
4 Gy, 3 h
4 Gy, 6 h

Persistence of gH2AX foci in Chd2 mutant cells

WT

+/m

m/m

0.88±1.45
18.23±3.54 (100)
10.1±2.57 (55.4)
3.43±1.86 (18.8)

1.65±1.73*
23.46±3.83** (100)
21.66±3.92** (92.3)
14.87±2.87*** (63.38)

2.8±2.3*
27.26±5.08** (100)
23.76±5.08** (87.1)
18.0±3.97*** (66.0)

Wild-type (WT) and Chd2 homozygous mutant MEFs were treated with X-ray irradiation (4 Gy) and ﬁxed at 30 min, 3 h and 6 h post-irradiation.
The gH2AX foci formation was visualized by immunoﬂuorescent staining with anti-gH2AX antibodies and ﬂuorescein isothiocyanate-labeled
secondary antibodies. A minimum of 30 cells were analysed per genotype and the numbers represent mean number of larger gH2AX foci per cell.
The percentage of foci remaining unresolved at 3 and 6 h with respect to the percentage obtained at 30 min (set independently at 100% for each
group) is shown within parenthesis. Experiments were performed with two separate sets (WT, +/m and m/m) of independently derived mouse
embryonic ﬁbroblasts that gave similar results. The differences between the WT and mutants (+/m and m/m) were statistically signiﬁcant
(*Po0.01, **Po0.0001 and ***Po0.0002). Bars represent s.d.

Figure 4 Defective DNA damage response in Chd2 mutant cells. Wild-type and Chd2 homozygous mutant littermate mouse
embryonic ﬁbroblasts (MEFs) were treated with 4 Gy X-ray irradiation and analysed for gH2AX foci formation at 30 min, 3 (data not
shown) and 6 h. For immunoﬂuorescence analysis, wild-type and mutant cells were grown in different chambers on the same slide.
Results were conﬁrmed with four experiments using two sets of independently derived cell lines. At least 30 cells were analysed per
experiment. All cells were photographed using the same exposure time and microscope settings. Bar ¼ 10 m.
Oncogene
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due to the resolution of DNA-strand breaks (Rothkamm et al., 2003). Comparison of the clearance of
gH2AX foci after 3 h (data not shown) and 6 h (last
panel) indicated a higher persistence of gH2AX foci in
the mutant cells (Figure 4, right panels). Semiquantitative analysis of gH2AX foci also showed that the
heterozygous and homozygous mutant cells were unable
to downregulate the gH2AX response, whereas the wildtype cells showed a robust clearance of gH2AX foci
within 6 h (Table 2 and Supplementary Figure 7).
Consistent with the defective clearance of gH2AX foci,
the Chd2 mutants were highly sensitive to a variety of
DNA-damaging agents (Supplementary Figure 8). The
Chd2 mutant MEFs also exhibited moderately higher
increase in the G1-S phase of the cell cycle in response to
X-ray-induced DNA damage in comparison with wildtype MEFs (Supplementary Table 3). These observations
indicate that the Chd2 mutant cells have defects in DNA
damage-induced gH2AX response and suggest a potential
role for Chd2 in either the repair of DNA-strand breaks
or the attenuation of the gH2AX signal after repair.
Discussion
The CHD proteins have distinct structural motifs that
implicate speciﬁc functional roles in a variety of DNA
transactions that include replication, transcription and
DNA repair. To further study the physiological role of
Chd2 in a mammalian model, we generated a Chd2
mutant mouse model using the Baygenomics gene-trap
ES cell resource. Characterization of the gene trap used
in the generation of the Chd2 mutant mouse model
indicated that it was not completely effective in
disrupting the expression of the Chd2 gene, suggesting
the possibility of a hypomorphic or a dominant negative
Chd2 mutant mouse model. We have shown through
protein interaction studies that the truncated Chd2-bgal-neomycin has a potential to interact with the native
Chd2 protein. However, our studies do not rule out the
possibility that the mutant Chd2 fusion protein can
either act as a dominant negative mutant or a gain of
function mutant. Future studies aimed at identifying
functional partners of Chd2 will allow us to determine
the effect of this mutation. The expression of wild-type
Chd2 mRNA in the homozygous mutant cells is in
contrast to the results reported earlier (Marfella et al.,
2006) and we believe that the discrepancy is due to the
low number of cycles in the reverse transcription–PCR
analysis used by the other group in comparison with
ours (26 cycles versus 30 cycles in this study). Our results
indicate that the Chd2 mutation leads to pleiotropic
effects that impinge on hematopoietic and lymphoid
development pathways in mammals. We have shown
that the CHD2 protein is involved in the regulation of
hematopoietic stem cell differentiation, and its loss may
lead to an imbalance in the various downstream
compartments that include the erythroid, myeloid and
lymphoid compartments. Interestingly, earlier studies
have shown the importance of differentiation and cell
type-speciﬁc transcriptional programming during the

terminal differentiation of hematopoietic cells and our
studies point to the role of chromatin remodeling and its
effects on transcription on hematopoietic stem cell
differentiation (Heyworth et al., 2002; Iwasaki et al.,
2003; Ney, 2006).
More importantly, the Chd2 mutant mice develop
primarily lymphomas and lymphoid hyperplasias. A few
of the phenotypes we have described in this report are
similar to the ones reported in a recent study involving
the phenotypic characterization of the Chd2 mutant
mouse model (Marfella et al., 2006). However, the
earlier study has not reported the susceptibility of
lymphomas in the Chd2 mutant mice and the differences
between the two studies may relate to the fact that our
study is more extensive that involved the analysis of a
larger set of mutant animals. Although the other study
does report the presence of lymphoid hyperplasia
(a precursor for lymphomas) in the mutants, the reasons
for the differences in lymphoma diagnoses between the
two studies are yet to be ascertained. Interestingly, the
human CHD2 chromosomal locus (15q26.2) is also
implicated in a rare genetic disorder that leads to growth
retardation, cardiac defects and early post-natal lethality
(Wilson et al., 1985; Whiteford et al., 2000). The data we
have compiled on human chromosomal aberrations
provide preliminary evidence that the Chd2 protein may
play a role in the etiology of human lymphoid tumors.
Furthermore and consistent with our observations, the
recent characterization of a T-cell Hodgkin’s lymphoma
cell line using array comparative genomic hybridization
analysis has also shown the homozygous loss of the
CHD2 chromosomal locus (Feys et al., 2007). The above
mentioned data and the enhanced tumor susceptibility
of the Chd2 heterozygous mice raise the possibility that
CHD2 is a potential tumor suppressor gene involved in
the suppression of lymphomas.
Our data also show that the Chd2 protein affects
DNA damage signaling and processing at the chromatin
level by modulating the levels of gH2AX induced by
DNA damage. Although several studies have shown
that a decrease in the gH2AX foci often mirrors a
decrease in the number of DNA-strand breaks, we
cannot rule out the possibility that the persistence of
gH2AX foci may relate to the inability of the Chd2
mutant cells to displace gH2AX subsequent to DNA
repair (Rogakou et al., 1998; Banath and Olive, 2003;
Rothkamm et al., 2003; Lukas et al., 2004; Jin et al.,
2005). Consistent with this notion, a recent study has
shown that the removal of gH2AX after DNA damage is
mediated by the Tip60 chromatin remodeling complex
(Kusch et al., 2004). In addition, DNA damage processing
in lower eukaryotes is mediated by the INO80 complex
and this complex requires the HMG1 domain-containing
Nhp10 subunit protein for its interaction with the gH2AX
(Morrison et al., 2004; van Attikum et al., 2004; Tsukuda
et al., 2005). Interestingly, the Chd2 protein contains a
similar domain, and the ability of Chd1 to transfer
histones to DNA also suggests a parallel and mutually
exclusive role for CHD2 in the removal of gH2AX (Lusser
et al., 2005). Whether Chd2 plays a functional role in
gH2AX removal during the attenuation of DNA damage
Oncogene
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response or directly affects DNA repair processes remains
to be seen.
The functional roles of CHD family members and
other chromatin remodeling proteins in transcriptional
regulation have been well established. However, our
data suggest that the CHD2 protein may play an
additional role in DNA damage signaling besides
affecting transcription. Determining the tissue-speciﬁc
transcriptional targets and the role of Chd2 in downstream DNA damage response pathways will provide
further insights on its functions in development,
hematopoietic stem cell differentiation and tissuespeciﬁc tumor suppression.

Materials and methods
Generation of Chd2 mutant mice
The Baygenomics insertional mutagenesis strategy involved
the use of a gene-trap cassette consisting of a splice-acceptorbgeo cassette (b-galactosidase-neomycin fusion gene).
Embryonic stem cell clones are then characterized by 50 RACE
to identify upstream exons abutting the bgeo sequence. One of
the ES cell clones that had been characterized to have a gene
trap insertion within the Chd2 gene was represented in the
Baygenomics ES cell library. The Chd2-trapped ES cells were
obtained and characterized further. Genomic DNA isolated
from ES cells were analysed by PCR to conﬁrm Chd2
disruption by using primers that were speciﬁc for Chd2 exon
27 (50 -TGTGTGTCAGCAATGCAGGA-30 ) and the genetrap sequences (50 -ACCTGGCTCCTATGGGATAG-30 ). Sequencing of the PCR product indicated that the gene trap was
integrated within intron 27 (1563 base pairs from the beginning
of the intron) of the Chd2 gene. Chd2-targeted ES cells were
used for blastocyst injections using the microinjection services
at the University of Massachusetts Medical School, Worcester.
The colonies from two germline founders were expanded
further for the analysis of the mutant offspring. The insertion
of the gene trap was determined to be downstream of the
HMG-1 DNA-binding domain and upstream of three
putative nuclear localization signals of Chd2. The gene-trap
strategy used to generate the Chd2 mutant ES cells also
leads to the generation of a putative truncated Chd2-bgeo
fusion protein containing the ﬁrst 1198 amino acids of the
wild-type protein. To conﬁrm the absence of the Chd2

protein in the nucleus, we used antibodies against the
b-galactosidase part of the fusion and found that the Chd2b-gal-neomycin fusion gene product was localized only in the
cytoplasm (not shown). All protocols and procedures involving the analysis of mutant mice were approved by the
University of Tennessee IACUC committee.
Analysis of gH2AX response in MEFs
Mouse embryonic ﬁbroblasts were grown on glass chamber
slides and exposed to 4 Gy X-ray irradiation and incubated for
the indicated time intervals. The cells were ﬁxed with acetonemethanol (1:1) and blocked with 10% antibody dilution buffer
(3% bovine serum antigen, 10% goat serum, 0.05% Triton
X-100 in phosphate-buffered saline). The slides were incubated
with anti-gH2AX antibodies (Cell Signal Technology, Beverly,
MA, USA) followed with ﬂuorescein isothiocyanate—conjugated anti-rabbit antibodies. The slides were counterstained
for DNA with DAPI and the gH2AX foci were visualized
using a ﬂuorescent microscope (Zeiss Axioplan) and acquired
with Metamorph software (Molecular Devices, Sunnyvale,
CA, USA).
Fetal liver colony assays
Single-cell suspensions (2  104) prepared from fetal livers of
E13.5 embryos were plated on 35 mm culture dishes with
semisolid complete methylcellulose medium (Methocult medium supplemented with stem cell factor, interleukin-3, interleukin-6 and erythropoietin, Stem Cell Technologies,
Vancouver, BC, Canada). Burst-forming unit-erythroids and
colony-forming unit-granulocyte macrophages were counted
after 8–10 days using morphological criteria.
Statistical analyses
Standard error, mean and P-values were determined using
the statistics software from Microsoft Excel. Kaplan–Meir
survival curves were generated and analysed with Prism 4
(GraphPad Software).
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